A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/201...

por Ocana, Alberto, Gil-Martin, Marta, Martín, Miguel, Rojo, Federico, Antolín, Silvia, Guerrero, Ángel, Trigo, José Manuel, Muñoz, Montse, Pandiella, Atanasio, Diego, Núria Gonzalo, Bezares, Susana, Caballero, Rosalía, Carrasco, Eva, Urruticoechea, Ander
Publicado 2017